Singapore leads SEA health tech and life sciences funding in 2024

Singapore raised a total of $92.4m in 2024.

Singapore led Southeast Asia in healthtech and life sciences funding in 2024, raising $92.4m across 14 rounds, Traxcn reported.

Jakarta followed at a distant second with $9m raised, whilst Kuala Lumpur comes next with $592,000.

The top funding rounds were also from Singapore, with HealthifyMe raising $20m in Series C, Biobot Surgical securing $17.9m in Series B, and Allozymes obtaining $15m in Series A.

Singapore’s Mistletoe ranked fourth amongst the most active accelerators and incubators, whilst Cocoon Capital placed fourth for VC seed, ZIG Ventures fifth for VC early stage, and Marubeni second for private equity.

Follow the link for more news on

Chart of the Day

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia